PAPP-A: A new anti-aging target?
Mayo Clinic Email Newsletter
By Cheryl A. Conover, Ph.D., of the Division of Endocrinology, Diabetes, Metabolism and Nutrition at Mayo Clinic in Rochester, Minn.,
A few summary points:
-       Cheryl A. Conover, Ph.D., strives for an extended, healthy life. She proposes pregnancy-associated plasma protein-A (PAPP-A) as a therapeutic target for aging and age-related disease.
-Â Â Â Â Â Â Â Although PAPP-A is found in high concentrations in pregnant women, it is also a therapeutic target for aging and age-related disease.
-Â Â Â Â Â Â Â PAPP-A is a novel zinc metalloprotease expressed by various nonreproductive cell types as well, including fibroblasts, vascular smooth muscle cells (SMCs) and osteoblasts.
-Â Â Â Â Â Â Â IGFs are associated with cellular and chronological aging
-Â Â Â Â Â Â Â Reduction of IGF-1 signaling has been shown to prolong life span in diverse species.
-Â Â Â Â Â Â Â Since PAPP-A enhances local IGF-1 action, inhibition of PAPP-A expression or proteolytic activity represents an innovative approach to decreasing IGF availability . . .
Dear Reader: This article is information rich. If you like what you’ve seen so far, please read the entire article to learn about the research methods and how PAPP-A works –
Then let’s get to work on how to use this to create aging solutions.
What I like most is the ending: the solutions oriented approach Dr. Conover and Jan van Deursen, Ph.D., at Mayo Clinic are taking.
Dr. Conover says “. . . we are developing therapies to inhibit PAPP-A’s proteolytic activity.” The long-term goals of this laboratory include:
• Generate specific therapies that target PAPP-A
• Screen efficacy of these inhibitors in vivo
• Determine safety and pharmacokinetic profiles of such inhibitors
• Initiate clinical trials to regulate longevity and to control complications of age-related diseases in humans
Dr. Conover and van Deursen – I will be in contact with you with more information about the GRG. Please keep us informed.
Related: Pregnancy-Associated Plasma Protein A as a Marker of Acute Coronary Syndromes
http://www.nejm.org/doi/full/10.1056/NEJMoa003147
Johnny
John M. “Johnny†Adams
Executive Director Gerontology Research Group
JAdams at sign grg dot org
(650) 265-4969
(949) 922-9786 cell
~~~~
CEO / Exec. Director
Carl I. Bourhenne Medical Research Foundation / Aging Intervention Foundation
http://www.AgingIntervention.org
http://www.AgingIntervention.org/JohnnyAdamsBackgroundSummary.htm